Literature DB >> 8592735

Giant cell arteritis as an antigen-driven disease.

C M Weyand1, J J Goronzy.   

Abstract

Emerging data support the model that giant cell arteritis (GCA) is an antigen-driven disease. Select helper T cells are recruited to the vascular lesions where they produce a defined pattern of cytokines. At least two functionally distinct populations of macrophages are involved and macrophage activation extends into the compartment of circulating phagocytes. Searches for the antigen may be facilitated through structural analysis of specially activated T lymphocytes in the lesions. In addition to the proposed disease-inducing agent, genetic risk factors are important. One of the genetic elements has been mapped to the HLA-DR region and seems to encode parts of a pocket in the HLA-DR molecule, accommodating side chains of the interacting antigenic peptide. On the molecular level, some but not all pathomechanisms are shared by polymyalgia rheumatica and GCA, indicating that both syndromes form a spectrum of disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8592735

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  14 in total

1.  Formation of new vasa vasorum in vasculitis. Production of angiogenic cytokines by multinucleated giant cells.

Authors:  M Kaiser; B Younge; J Björnsson; J J Goronzy; C M Weyand
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

Review 2.  Combination therapy in autoimmune disease: vasculitis.

Authors:  D Carruthers; P Bacon
Journal:  Springer Semin Immunopathol       Date:  2001

3.  A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis.

Authors:  Carol A Langford; David Cuthbertson; Steven R Ytterberg; Nader Khalidi; Paul A Monach; Simon Carette; Philip Seo; Larry W Moreland; Michael Weisman; Curry L Koening; Antoine G Sreih; Robert Spiera; Carol A McAlear; Kenneth J Warrington; Christian Pagnoux; Kathleen McKinnon; Lindsy J Forbess; Gary S Hoffman; Renée Borchin; Jeffrey P Krischer; Peter A Merkel
Journal:  Arthritis Rheumatol       Date:  2017-03-03       Impact factor: 10.995

4.  Aldose reductase functions as a detoxification system for lipid peroxidation products in vasculitis.

Authors:  H L Rittner; V Hafner; P A Klimiuk; L I Szweda; J J Goronzy; C M Weyand
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

Review 5.  IFN-γ and IL-17: the two faces of T-cell pathology in giant cell arteritis.

Authors:  Cornelia M Weyand; Brian R Younge; Jörg J Goronzy
Journal:  Curr Opin Rheumatol       Date:  2011-01       Impact factor: 5.006

6.  Interferon-gamma-producing T cells in giant cell vasculitis represent a minority of tissue-infiltrating cells and are located distant from the site of pathology.

Authors:  A D Wagner; J Björnsson; G B Bartley; J J Goronzy; C M Weyand
Journal:  Am J Pathol       Date:  1996-06       Impact factor: 4.307

7.  Reactive nitrogen intermediates in giant cell arteritis: selective nitration of neocapillaries.

Authors:  Astrid Borkowski; Brian R Younge; Luke Szweda; Bettina Mock; Johannes Björnsson; Kerstin Moeller; Jörg J Goronzy; Cornelia M Weyand
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

8.  Selective T cell receptor decrease in peripheral blood T lymphocytes of patients with polymyalgia rheumatica and giant cell arteritis.

Authors:  M Lopez-Hoyos; M J Bartolome-Pacheco; R Blanco; V Rodriguez-Valverde; V M Martinez-Taboada
Journal:  Ann Rheum Dis       Date:  2004-01       Impact factor: 19.103

9.  Correlation of the topographical arrangement and the functional pattern of tissue-infiltrating macrophages in giant cell arteritis.

Authors:  C M Weyand; A D Wagner; J Björnsson; J J Goronzy
Journal:  J Clin Invest       Date:  1996-10-01       Impact factor: 14.808

10.  Bevacizumab plus ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Donald Lawrence; Cecilia Lezcano; Xinqi Wu; Jun Zhou; Tetsuro Sasada; Wanyong Zeng; Anita Giobbie-Hurder; Michael B Atkins; Nageatte Ibrahim; Philip Friedlander; Keith T Flaherty; George F Murphy; Scott Rodig; Elsa F Velazquez; Martin C Mihm; Sara Russell; Pamela J DiPiro; Jeffrey T Yap; Nikhil Ramaiya; Annick D Van den Abbeele; Maria Gargano; David McDermott
Journal:  Cancer Immunol Res       Date:  2014-04-21       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.